Current European Legal Framework concerning the use of Medical Cannabis

December 4, 2019
European-Union-cannabis-legal-aspects-1200x708.jpg

Legal Medicinal Cannabis in Europe

As the cannabis market has boomed and new scientific discoveries arise, legislation has become a topic in question which has put a lot of pressure on governments around Europe.

International Drug Policy Consortium Regulations

There are two main kinds of regulation that the International Drug Policy Consortium (IDPC) have established in 2018. The first one comes from the government’s will to improve public health which has resulted into policy. In certain cases, recreational cannabis goes hand in hand with this as well, for example, Canada. The second one comes from the social pressures and the citizen’s initiative to fight for the legalisation which is essentially the case in the UK in which they offer a legal license to patients who comply with strict requirements.

The difficulty in legalising medicinal cannabis

Back in 1961, cannabis was under the Single Convention on Narcotic Drugs meaning it was internationally prohibited, essentially putting an end to medical and scientific research. From this ban, for countries to be able to adopt to the new regulations, there must be irrefutable evidence showcasing the therapeutic uses of the substance. Without the backing of a strong scientific foundation, legalising medicinal cannabis can become challenging.

A few European countries are close to regulating medicinal cannabis

• The United Kingdom

In the UK, the Department of Health was forced to grant emergency licences to two severe cases of epilepsy in children which consequently began a process to allow access to the medicine. However, this is only allowed in certain conditions such as refractory epilepsy, spasticity, multiple sclerosis and chemotherapy induced nausea and vomiting. It is also necessary for the patients to have undergone all kinds of conventional treatments which have failed. After presenting all the necessary documents, only the Department of Health can determine if the patient can gain access.

• Germany

Medicinal cannabis was legalised in Germany in 2017 and is one of the first countries to regulate medicinal cannabis in public and private health sectors. To begin treatment, patients must go through a health insurance company, which will then be reimbursed by the government. Cannabis cultivation is also allowed if companies have enough experience.

• Italy

In 2015, the Italian Minister of Health released a legislation wherein physicians are able to prescribe patients with medicinal cannabis only if the condition can be backed by scientific literature. Similar to the UK, it is only available if previous treatment has failed.

• Denmark

In 2018, the Danish Parliament released a 4-year programme allowing doctors to prescribe medicinal cannabis products only if standard treatments have failed.

• Netherlands

The Netherlands is the only country that does not have the stigma that other countries may have, and doctors’ reputations aren’t tarnished if they prescribe medicinal cannabis. Cannabis in the Netherlands is under a lower classification drug compared to other countries and can also be prescribed by doctors if previous standard treatments have failed.

Is medicinal cannabis a necessity?

The World Health Organisation (WHO) as well as the Expert Committee on Drug Dependence (ECDD) has recommended for cannabis to be removed from the highest classification of drugs and that its therapeutic importance should be recognised. The European Parliament has also made it known that cannabis is a medicinal necessity. On that, as many important entities have had similar statements, medicinal cannabis should be seen as a necessity by everyone.

Source: https://www.kalapa-clinic.com/en/use-medical-cannabis-legal-framework/

Logo Can Pharma SVG

CanPharma has a pharmaceutical wholesale permission according to §52a of the German Medicines Act, as well as a license to handle narcotics in the meaning of §3 of the German narcotics legislation. Furthermore, CanPharma has a GDP-certified quality assurance system.

MEMBER OF

OFFICES

CanPharma GmbH
Wiesbadener Str. 29,
16515 Oranienburg, Germany

 

REPRESENTATIVE OFFICES

Berlin
Rosenthaler Str. 34
10178 Berlin
Germany

Barcelona
Gran de Gràcia 15, 1-1
08012 Barcelona
Spain